tonabacase
Recombinant proteinexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01855048)
Timeline
Indications
Mechanism of action
- LysozymeSupplementation
E supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- n-rephasin sal200
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05329168 | Phase 2 | May 1, 2022 | Urovant Sciences Ltd. |
| NCT03446053 | Phase 1 | Feb 7, 2018 | Intron Biotechnology, Inc., Seoul National University |
| NCT03089697 | Phase 2 | Mar 7, 2017 | Intron Biotechnology, Inc., Seoul National University |
| NCT01855048 | Phase 1 | Aug 1, 2013 | Intron Biotechnology, Inc., Seoul National University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intron Biotechnology, Inc. | For profit | 3 | 3 | 2 | 2013 |
| Seoul National University | Academic/Hospital | 3 | 0 | 2 | 2013 |
| Urovant Sciences Ltd. | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1